These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22863920)

  • 1. Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.
    Onzawa Y; Kimura Y; Uzuhashi K; Shirasuna M; Hirosawa T; Taogoshi T; Kihira K
    Biol Pharm Bull; 2012; 35(8):1244-8. PubMed ID: 22863920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 3-O-methyldopa in the side effects of L-dopa.
    Lee ES; Chen H; King J; Charlton C
    Neurochem Res; 2008 Mar; 33(3):401-11. PubMed ID: 17713853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
    Nakazato T; Akiyama A
    Brain Res; 2002 Mar; 930(1-2):134-42. PubMed ID: 11879803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
    Kaakkola S; Wurtman RJ
    J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
    Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
    Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
    Reches A; Fahn S
    Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
    Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
    Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
    Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
    J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
    Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
    Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
    Tohgi H; Abe T; Kikuchi T; Takahashi S; Nozaki Y
    Neurosci Lett; 1991 Oct; 132(1):19-22. PubMed ID: 1787913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.
    Männistö PT; Tuomainen P; Toivonen M; Törnwall M; Kaakkola S
    J Neural Transm Park Dis Dement Sect; 1990; 2(1):31-43. PubMed ID: 2113389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopamine metabolites on locomotor activities and on the binding of dopamine: relevance to the side effects of L-dopa.
    Charlton CG; Crowell B
    Life Sci; 2000 Apr; 66(22):2159-71. PubMed ID: 10834300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
    Schneider F; Erisson L; Beygi H; Bradbury M; Cohen-Barak O; Grachev ID; Guzy S; Loupe PS; Levi M; McDonald M; Savola JM; Papapetropoulos S; Tracewell WG; Velinova M; Spiegelstein O
    Br J Clin Pharmacol; 2018 Oct; 84(10):2422-2432. PubMed ID: 29959802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.